| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 7.41 mm | 6.88 mm | 6.99 mm | 7.08 mm |
| Cash used (since last report) | n/a | n/a | 209.62 mm | 194.44 mm | 197.68 mm | 200.21 mm |
| Cash remaining | n/a | n/a | 82.94 mm | 98.12 mm | 94.88 mm | 92.35 mm |
| Runway (months of cash) | n/a | n/a | 11.2 | 14.3 | 13.6 | 13.0 |
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 30.04 mm |
| Total shares | 5.49 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CinRx Pharma | 3.63 mm | $0.00 |
| venBio Global Strategic Fund III | 1.86 mm | $30.04 mm |
| Proequities | 0.00 | $0.00 |
